Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan

Abstract

Background Although immune checkpoint inhibitors (ICIs) are promising in the treatment of advanced cancer, their use is associated with immune-related adverse events (irAEs) that affect endocrine organ systems. Although development of irAEs was associated with improved cancer-specific survival, the risk of irAEs is unclear. We investigated the association of pre-ICI comorbidities—including diabetes—with irAEs, overall survival (OS), and progression-free survival (PFS) in advanced lung cancer. Methods Patients with lung cancer who were treated with ICIs during the period from September 1, 2015 through July 31, 2018 were retrospectively enrolled. All data were collected from the NEPTUNE database of university patients. Hazard ratios were estimated by using Cox regression weighted for propensity scores. Odds ratios were calculated by logistic regression and adjusted for unbalanced variables. The Kaplan–Meier method was used to compare OS, and the generalized Wilcoxon test was used to compare median survival. Results Among the 88 patients identified, 22 (25.0%) had diabetes (DM) before ICI treatment and 57 (75.0%) did not (non-DM); irAEs developed in 12.2% of patients with DM and in 9.1% of patients in non-DM (p=0.87). Diabetes status was not associated with irAE risk in relation to baseline characteristics (age, sex, TNM staging, thyroid and renal function) or in propensity score–matched analysis (age, TNM staging). During a mean follow-up of 30 months, OS and cancer-specific PFS were significantly higher in patients who developed irAEs (Kaplan–Meier estimates, p=0·04 and 0·03, respectively). In propensity score–matched analysis, diabetes was significantly associated with lower OS (multivariate hazard ratio, 0·36; 95% CI, 0·13–0·98) unrelated to irAEs. Irrespective of irAEs, PFS was also lower among patients with DM than among non-DM patients (Kaplan–Meier estimate, p=0·04). Conclusion Pre-existing diabetes was associated with higher mortality in advanced lung cancer, regardless of irAE development during treatment with ICI.

"Negative Association between Diabetes Mellitus and the Efficacy of Cancer Immunotherapy"

“…Finally, four papers were included in the Meta-analysis had a total of 3065 cancer patients of which 1509 cancer patients had diabetes mellitus and a form of cancer while 1556 patients did not have diabetes mellitus. Although the total population is large, disparity in terms of representations across the four studies is evident [11][12][13][14]. For example, study selection and contribution to this meta-analysis leads to one study contributing to the majority of participants so that 2600 cancer patients and 1395 DM patients are from a single study.…”

Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic mice

“…Immune checkpoint inhibitors (ICIs), including antibodies against programmed cell death-1 (PD-1) and PD-1 ligand-1 (PD-L1), induce their anti-tumor effects by improving the function of immune cells 11 . Two retrospective studies from Israel 12 and Japan 13 recently reported that diabetes was negatively correlated to overall survival in patients with non-small cell lung cancer (NSCLC) treated with ICIs. However, the mechanisms behind this impaired outcome of ICI treatments in diabetic patients remain unknown.…”